Patients with HR‐positive/HER2‐negative advanced breast cancer who had received endocrine therapy were enrolled in the SOLAR‐1 trial [30], and the efficacy and safety of fulvestrant and alpelisib combination therapy were assessed in comparison with fulvestrant and placebo. Here, ERBB2 is linked to breast carcinoma.